To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL
A phase 1/2 trial of Tafasitamab, Lenalidomide in diffuse large b-cell lymphoma, run by Incyte Biosciences Japan GK, active and no longer recruiting.
Overview
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) is a phase 1/2 interventional study registered as NCT04661007 by Incyte Biosciences Japan GK, with 72 participants enrolled, started 2020-12-15 and due to reach its primary completion in 2025-07-01. Interventions recorded: tafasitamab, lenalidomide, parsaclisib, R-CHOP. Conditions listed: Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSafety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
Shares Tafasitamab, Incyte, Lenalidomide, Diffuse large B-cell lymphoma.
- TrialStudy to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (
Shares Tafasitamab, Incyte, Lenalidomide, Diffuse large B-cell lymphoma.
- TrialL-MIND
Shares Tafasitamab, Lenalidomide, Diffuse large B-cell lymphoma.
- TrialA Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa
Shares Tafasitamab, Incyte, Lenalidomide.
- TrialRollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Shares Parsaclisib, Incyte.
- TrialExtension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Shares Tafasitamab, Incyte.
- TrialfrontMIND
Shares Tafasitamab, Lenalidomide, Diffuse large B-cell lymphoma.
- CompanyMorphoSys (Novartis)
Shares Tafasitamab, Diffuse large B-cell lymphoma.